Secondary Logo

Journal Logo

Institutional members access full text with Ovid®

Cytokine expression and dendritic cell density in melanoma sentinel nodes

Botella-Estrada, Rafaela; Dasí, Franciscob c; Ramos, Davidd; Nagore, Eduardoa; Herrero, Maria Joseb; Giménez, Juliae; Fuster, Carlose; Sanmartín, Onofrea; Guillén, Carlosa; Aliño, Salvadorb

ORIGINAL ARTICLES
Buy

The sentinel lymph node (SLN) is the first draining node from the area in which a tumour is located. The presence or absence of SLN micrometastasis is an important prognostic factor for melanoma. As the first dissemination route for melanoma is lymphatic and we know that the immune system plays an important role in melanoma response, we hypothesize that melanoma and its corresponding SLN should constitute an immunological unit. Small portions of 54 SLNs from 37 patients undergoing selective lymphadenectomy were subjected to quantitative reverse transcriptase-polymerase chain reaction (qRT-PCR) to quantify messenger RNA (mRNA) transcripts of the following genes: tyrosinase, telomerase, cyclooxygenase-1 (COX-1), COX-2, granulocyte–macrophage colony-stimulating factor (GM-CSF), interleukin-2 (IL-2), interferon-γ (IFN-γ), IL-4, IL-10 and IL-12. In addition, 11 non-sentinel lymph nodes (NSLNs) were excised from 11 of the 37 patients and the same study was performed. Immunohistochemistry with different antibodies against dendritic cells (DCs) was performed in 10 pairs of SLNs and NSLNs. Significantly higher mRNA expression of COX-2, GM-CSF, IFN-γ and IL-10 was found in SLNs compared with NSLNs in the overall group. DCs, as labelled by S-100 and CD1a, were significantly decreased in NSLNs compared with SLNs. These data suggest that the initial increase in GM-CSF observed in SLNs could lead to the attraction of a high number of DCs to SLNs. However, the presence of certain immunosuppressive molecules, such as IL-10 and COX-2, could block their maturation and their ability to become efficient antigen presenters.

aDepartment of Dermatology, Instituto Valenciano de Oncología, Valencia, Spain

Departments of bPharmacology

cUnidad Central de Investigacón Medicina

dPathology, School of Medicine, University of Valencia, Valencia, Spain

eDepartment of Surgery, Instituto Valenciano de Oncología, Valencia, Spain

Sponsorship: This study was supported by Grant PI021679 Instituto de Salud Carlos III.

Correspondence and requests for reprints to Rafael Botella-Estrada, General Elio 4–13, 46010 Valencia, Spain

Tel: +34-963624041; fax: +34-961114341;

e-mail: rbot@eresmas.net

Received 9 July 2004 Accepted (after revision) 13 December 2004

© 2005 Lippincott Williams & Wilkins, Inc.